Jason H Gill
Overview
Explore the profile of Jason H Gill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Redgrave R, Dookun E, Booth L, Encina M, Folaranmi O, Tual-Chalot S, et al.
NPJ Aging
. 2023 Jun;
9(1):16.
PMID: 37353486
No abstract available.
2.
Redgrave R, Dookun E, Booth L, Encina M, Folaranmi O, Tual-Chalot S, et al.
NPJ Aging
. 2023 Jun;
9(1):15.
PMID: 37316516
Myocardial infarction is a leading cause of morbidity and mortality. While reperfusion is now standard therapy, pathological remodelling leading to heart failure remains a clinical problem. Cellular senescence has been...
3.
Abdelghany T, Hedya S, De Santis C, Abd El-Rahman S, Gill J, Abdelkader N, et al.
Ecotoxicol Environ Saf
. 2023 Jun;
249:114439.
PMID: 37272551
Methylimidazolium ionic liquids (MILs) are solvent chemicals used in industry. Recent work suggests that MILs are beginning to contaminate the environment and lead to exposure in the general population. In...
4.
Philip L, Findlay S, Gill J
Int J Cardiol Cardiovasc Risk Prev
. 2022 Dec;
15:200153.
PMID: 36573186
Aims: Anthracyclines, a mainstay of cancer treatment, are associated with significant life-threatening cardiotoxicity. As cancer survivorship improves, there is a growing need to identify patients most at risk and strategies...
5.
Booth L, Redgrave R, Folaranmi O, Gill J, Richardson G
Front Aging
. 2022 Dec;
3:1058435.
PMID: 36452034
Cancer continues to place a heavy burden on healthcare systems around the world. Although cancer survivorship continues to improve, cardiotoxicity leading to cardiomyopathy and heart failure as a consequence of...
6.
Brown A, Aljohani A, Alsalem F, Broadhead J, Gill J, Lu Y, et al.
Molecules
. 2020 May;
25(10).
PMID: 32455566
Discovery and development of new therapeutic options for the treatment of () infection, particularly drug-resistant strains, are urgently required to tackle the global burden of this disease. Herein, we reported...
7.
Cross J, Blower T, Gallagher N, Gill J, Rockley K, Walton J
Chempluschem
. 2020 Jan;
81(12):1276-1280.
PMID: 31964062
The first examples of Ru and Rh piano-stool complex histone deacetylase (HDAC) inhibitors are presented. The novel complexes have antiproliferative activity against H460 non-small-cell lung carcinoma cells that is comparable...
8.
Mansley M, Roe A, Francis S, Gill J, Bailey M, Wilson S
Br J Pharmacol
. 2019 Aug;
176(24):4708-4719.
PMID: 31423568
Background And Purpose: Aldosterone stimulates epithelial Na channel (ENaC)-dependent Na retention in the cortical collecting duct (CCD) of the kidney by activating mineralocorticoid receptors that promote expression of serum and...
9.
Walker E, Roberts R, Gill J
Toxicol Res (Camb)
. 2019 Jul;
8(4):480-488.
PMID: 31341610
To ascertain attitudes to resourcing, collaboration and publication in toxicology, a survey was developed and distributed to British Toxicology Society (BTS) members. The survey comprised 14 questions with 5 response...
10.
Gill J, Rockley K, De Santis C, Mohamed A
Pharmacol Ther
. 2019 Jun;
202:18-31.
PMID: 31173840
Destruction of the established tumour vasculature by a class of compound termed Vascular Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the management of solid tumours....